Chronic Rhinitis
Conditions
Brief summary
Evaluation of the Aerin Medical Device used for the treatment of chronic rhinitis
Detailed description
This is a non-significant risk, prospective, multi-center, non-randomized study to evaluate the safety and efficacy of the Aerin Medical device (InSeca Stylus) when used to deliver radiofrequency (RF) energy to the posterior nasal nerve area to improve symptoms in those diagnosed with chronic rhinitis.
Interventions
Low power radiofrequency energy delivery to the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus).
Sponsors
Study design
Intervention model description
All enrolled subjects will be treated with the InSeca Stylus
Eligibility
Inclusion criteria
1. Age 22 to 75 years (inclusively) 2. Willing and able to provide informed consent 3. Willing and able to comply with the subject-specific requirements outlined in the study protocol 4. Seeking treatment for chronic rhinitis symptoms of at least 6 months duration and willing to undergo an office-based procedure 5. Moderate to severe symptoms of rhinorrhea (rTNSS rating of 2 or 3 for rhinorrhea) 6. Mild to severe symptoms of nasal congestion (rTNSS rating of 1, 2 or 3 for congestion) 7. rTNSS score of greater than or equal to 6 8. Dissatisfaction with medical management, defined as usage of intranasal steroids for a minimum of 4 weeks without adequate symptom relief, as judged by the subject
Exclusion criteria
1. Anatomic obstructions that in the investigator's opinion limit access to the posterior nose 2. Altered anatomy of the posterior nose as a result of prior sinus or nasal surgery or injury 3. Active nasal or sinus infection 4. Moderate to severe ocular allergic symptoms (such as eye tearing \[epiphora\], itching \[pruritus\], or redness \[erythema\]) 5. History of significant dry eye 6. History of any of the following: nose bleeds in the past 3 months, rhinitis medicamentosa, head or neck irradiation 7. Known or suspected allergies or contraindications to the anesthetic agents and/or antibiotic medications to be used during the study procedure session 8. Known or suspected to be pregnant, or is lactating 9. Participating in another clinical research study 10. Other medical conditions which in the opinion of the investigator would predispose the subject to poor wound healing, increased surgical risk, or poor compliance with the requirements of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Reflective Total Nasal Symptom Score (rTNSS) | Comparison of scores at Baseline and 12 weeks post procedure | Mean change in Reflective Total Nasal Symptoms Score (rTNSS) from baseline to 12 weeks post-study procedure. Improvement (12 week score - baseline score) is signified by a negative value. The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. This study will measure the mean change in the rTNSS total score from Baseline to 12 week follow up visit |
| Percentage of Participants With Treatment Related Adverse Events (Safety) | At or following the study procedure, and up to the final study visit at 1 year. | Characterization of the type and frequency of treatment-related adverse events reported during or following the study procedure. Subjects were asked about possible side effects or adverse experiences related to the study procedure at each follow up visit. Each event was documented and identified as to its relationship and level of relatedness to the study device and/or study procedure. This measure includes any subject who experienced at least one event considered definitely, probably, or possibly related to the device or procedure. |
Other
| Measure | Time frame | Description |
|---|---|---|
| rTNSS Responder Rate | Comparison of scores at Baseline and 12 weeks post procedure | The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. Subjects who showed at least a 1 point improvement (decrease) in the reflective Total Nasal Symptom Score (rTNSS) were categorized as responders. An overall responder rate of at least 55% was expected. |
| Change in rTNSS Over Time | Baseline to each Follow Up Visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure. | Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores range from 0 to 12. A higher score indicates increased symptom severity. The mean change in the rTNSS total score from Baseline to each follow up visit: 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure will be recorded. |
| Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Baseline to each Follow Up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure | Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. Scores from each of the four components of the questionnaire (rhinorrhea, nasal congestion, nasal itching, and sneezing) will be evaluated at each follow up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure. Individual component scores can range from 0 to 3, with a higher score indicating increased symptom severity. |
| Response on Aerin Quality-of-Life (QOL) Assessment Items | The QOL was to be completed by the subject at baseline prior to the treatment procedure, and at the 12 week, 26 week and 52 week visits post procedure. | This Quality-of-Life (QOL) instrument is a 9-item patient self-reported questionnaire developed by Aerin Medical to gain understanding of the impact of chronic rhinitis on daily activities, feelings, symptoms and medication use. Each item had 5 possible answers to convey the following responses: very positive, positive, neutral, negative and very negative. Section 1 asks Please indicate how often you experience the following for 6 items. For items 1, 3, 4 and 5, those who answered never/rarely were considered to have a positive (favorable) response. For questions 2 and 6, those who answered frequently/very frequently were considered to have a positive (favorable) response. Section 2 requests Please indicate how often you use each of the following products to help you with your chronic rhinitis. For 3 items in this section, those who answered never/rarely were considered to have a positive (favorable) response. |
Countries
United States
Participant flow
Recruitment details
Patients in the specialist's clinic seeking treatment for chronic rhinitis symptoms of at least 6 months duration were approached for possible participation. Following completion of the informed consent process, baseline evaluation was conducted.
Pre-assignment details
Three potential subjects failed to meet one or more of the inclusion/exclusion criteria.
Participants by arm
| Arm | Count |
|---|---|
| InSeca Stylus Treatment Group Subjects treated with low power radiofrequency energy applied to the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus) | 50 |
| Total | 50 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Lost to Follow-up | 1 |
| Overall Study | Withdrawal by Subject | 2 |
Baseline characteristics
| Characteristic | InSeca Stylus Treatment Group |
|---|---|
| Age, Continuous | 57.9 years STANDARD_DEVIATION 11.9 |
| Body Mass Index | 29.8 kg/m2 STANDARD_DEVIATION 6.4 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 49 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 2 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 47 Participants |
| Region of Enrollment United States | 50 participants |
| rTNSS | 8.5 score on a scale STANDARD_DEVIATION 1.8 |
| Sex: Female, Male Female | 29 Participants |
| Sex: Female, Male Male | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 50 |
| other Total, other adverse events | 31 / 50 |
| serious Total, serious adverse events | 2 / 50 |
Outcome results
Change in Reflective Total Nasal Symptom Score (rTNSS)
Mean change in Reflective Total Nasal Symptoms Score (rTNSS) from baseline to 12 weeks post-study procedure. Improvement (12 week score - baseline score) is signified by a negative value. The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. This study will measure the mean change in the rTNSS total score from Baseline to 12 week follow up visit
Time frame: Comparison of scores at Baseline and 12 weeks post procedure
Population: The analyzed population excludes one subject who did not complete the rTNSS questionnaire at the 12 week follow-up visit due to oversight.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| InSeca Stylus Treatment Group | Change in Reflective Total Nasal Symptom Score (rTNSS) | -5.1 units on a scale | Standard Deviation 2.6 |
Percentage of Participants With Treatment Related Adverse Events (Safety)
Characterization of the type and frequency of treatment-related adverse events reported during or following the study procedure. Subjects were asked about possible side effects or adverse experiences related to the study procedure at each follow up visit. Each event was documented and identified as to its relationship and level of relatedness to the study device and/or study procedure. This measure includes any subject who experienced at least one event considered definitely, probably, or possibly related to the device or procedure.
Time frame: At or following the study procedure, and up to the final study visit at 1 year.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| InSeca Stylus Treatment Group | Percentage of Participants With Treatment Related Adverse Events (Safety) | 8 Participants |
Change in rTNSS Individual Nasal Symptom Component Scores Over Time
Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. Scores from each of the four components of the questionnaire (rhinorrhea, nasal congestion, nasal itching, and sneezing) will be evaluated at each follow up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure. Individual component scores can range from 0 to 3, with a higher score indicating increased symptom severity.
Time frame: Baseline to each Follow Up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| InSeca Stylus Treatment Group | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Rhinorrhea | 2.5 score on a scale | Standard Deviation 0.5 |
| InSeca Stylus Treatment Group | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Nasal Congestion | 2.5 score on a scale | Standard Deviation 0.6 |
| InSeca Stylus Treatment Group | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Nasal Itching | 1.7 score on a scale | Standard Deviation 0.9 |
| InSeca Stylus Treatment Group | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Sneezing | 1.9 score on a scale | Standard Deviation 0.8 |
| Treatment Group - 2 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Rhinorrhea | 1.6 score on a scale | Standard Deviation 0.9 |
| Treatment Group - 2 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Nasal Itching | 0.7 score on a scale | Standard Deviation 0.8 |
| Treatment Group - 2 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Nasal Congestion | 1.5 score on a scale | Standard Deviation 1 |
| Treatment Group - 2 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Sneezing | 1.0 score on a scale | Standard Deviation 0.7 |
| Treatment Group - 4 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Nasal Congestion | 1.1 score on a scale | Standard Deviation 0.8 |
| Treatment Group - 4 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Rhinorrhea | 1.2 score on a scale | Standard Deviation 0.8 |
| Treatment Group - 4 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Sneezing | 0.8 score on a scale | Standard Deviation 0.6 |
| Treatment Group - 4 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Nasal Itching | 0.4 score on a scale | Standard Deviation 0.6 |
| Treatment Group - 12 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Sneezing | 0.9 score on a scale | Standard Deviation 0.8 |
| Treatment Group - 12 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Rhinorrhea | 1.0 score on a scale | Standard Deviation 0.7 |
| Treatment Group - 12 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Nasal Congestion | 1.1 score on a scale | Standard Deviation 0.8 |
| Treatment Group - 12 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Nasal Itching | 0.5 score on a scale | Standard Deviation 0.7 |
| Treatment Group - 26 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Sneezing | 0.8 score on a scale | Standard Deviation 0.7 |
| Treatment Group - 26 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Rhinorrhea | 0.9 score on a scale | Standard Deviation 0.8 |
| Treatment Group - 26 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Nasal Itching | 0.5 score on a scale | Standard Deviation 0.7 |
| Treatment Group - 26 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Nasal Congestion | 1.1 score on a scale | Standard Deviation 0.8 |
| Treatment Group - 52 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Nasal Congestion | 1.2 score on a scale | Standard Deviation 1 |
| Treatment Group - 52 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Rhinorrhea | 1.1 score on a scale | Standard Deviation 0.8 |
| Treatment Group - 52 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Nasal Itching | 0.5 score on a scale | Standard Deviation 0.7 |
| Treatment Group - 52 Week Data | Change in rTNSS Individual Nasal Symptom Component Scores Over Time | Sneezing | 0.8 score on a scale | Standard Deviation 0.8 |
Change in rTNSS Over Time
Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores range from 0 to 12. A higher score indicates increased symptom severity. The mean change in the rTNSS total score from Baseline to each follow up visit: 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure will be recorded.
Time frame: Baseline to each Follow Up Visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure.
Population: 50 subjects were enrolled. 2 week evaluation: 1 subject missed it due to unrelated illness. 4 week evaluation: 1 subject missed it due to travel; 1 other attended the visit but did not complete the questionnaire. 12 week evaluation: All subjects attended but 1 subject did not complete the questionnaire. 26 week evaluation: 2 subjects withdrew from the study prior to the visit. 52 week evaluation: 1 additional subject was lost to follow-up.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| InSeca Stylus Treatment Group | Change in rTNSS Over Time | 8.5 score on a scale | Standard Deviation 1.8 |
| Treatment Group - 2 Week Data | Change in rTNSS Over Time | 4.8 score on a scale | Standard Deviation 2.4 |
| Treatment Group - 4 Week Data | Change in rTNSS Over Time | 3.6 score on a scale | Standard Deviation 2.1 |
| Treatment Group - 12 Week Data | Change in rTNSS Over Time | 3.4 score on a scale | Standard Deviation 2.3 |
| Treatment Group - 26 Week Data | Change in rTNSS Over Time | 3.3 score on a scale | Standard Deviation 2.1 |
| Treatment Group - 52 Week Data | Change in rTNSS Over Time | 3.6 score on a scale | Standard Deviation 2.3 |
Response on Aerin Quality-of-Life (QOL) Assessment Items
This Quality-of-Life (QOL) instrument is a 9-item patient self-reported questionnaire developed by Aerin Medical to gain understanding of the impact of chronic rhinitis on daily activities, feelings, symptoms and medication use. Each item had 5 possible answers to convey the following responses: very positive, positive, neutral, negative and very negative. Section 1 asks Please indicate how often you experience the following for 6 items. For items 1, 3, 4 and 5, those who answered never/rarely were considered to have a positive (favorable) response. For questions 2 and 6, those who answered frequently/very frequently were considered to have a positive (favorable) response. Section 2 requests Please indicate how often you use each of the following products to help you with your chronic rhinitis. For 3 items in this section, those who answered never/rarely were considered to have a positive (favorable) response.
Time frame: The QOL was to be completed by the subject at baseline prior to the treatment procedure, and at the 12 week, 26 week and 52 week visits post procedure.
Population: The baseline QOL was not completed by 4 subjects enrolled in the study. 12 week evaluation: 2 subjects failed to complete the QOL. 26 week evaluation: 2 subjects withdrew from the study prior to the 26 week visit. 52 week evaluation: 1 additional subject was lost to follow-up at this visit.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 5: Feelings of embarrassment or self-consciousness | Neutral or Negative response | 36 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 5: Feelings of embarrassment or self-consciousness | Positive (favorable) response | 10 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 3: Feeling fatigued during the day | Neutral or Negative response | 43 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 3: Nasal breathing strips | Neutral or Negative response | 5 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 4: Feelings of frustration/restlessness/irritability | Neutral or Negative response | 39 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 4: Feelings of frustration/restlessness/irritability | Positive (favorable) response | 7 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 2: Nasal sprays | Neutral or Negative response | 37 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 2: Nasal sprays | Positive (favorable) response | 9 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 2: Good sleep throughout the night | Positive (favorable) response | 11 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 1: Difficulty falling asleep | Positive (favorable) response | 5 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 1: Oral medications | Neutral or Negative response | 36 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 1: Oral medications | Positive (favorable) response | 10 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 2: Good sleep throughout the night | Neutral or Negative response | 35 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 3: Nasal breathing strips | Positive (favorable) response | 41 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 6: Having a good sense of overall well-being | Neutral or Negative response | 22 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 1: Difficulty falling asleep | Neutral or Negative response | 41 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 6: Having a good sense of overall well-being | Positive (favorable) response | 24 Participants |
| InSeca Stylus Treatment Group | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 3: Feeling fatigued during the day | Positive (favorable) response | 3 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 2: Good sleep throughout the night | Positive (favorable) response | 28 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 1: Difficulty falling asleep | Positive (favorable) response | 23 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 1: Difficulty falling asleep | Neutral or Negative response | 25 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 2: Good sleep throughout the night | Neutral or Negative response | 20 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 3: Feeling fatigued during the day | Positive (favorable) response | 17 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 3: Feeling fatigued during the day | Neutral or Negative response | 31 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 4: Feelings of frustration/restlessness/irritability | Positive (favorable) response | 30 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 4: Feelings of frustration/restlessness/irritability | Neutral or Negative response | 18 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 5: Feelings of embarrassment or self-consciousness | Positive (favorable) response | 38 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 5: Feelings of embarrassment or self-consciousness | Neutral or Negative response | 10 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 6: Having a good sense of overall well-being | Positive (favorable) response | 36 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 6: Having a good sense of overall well-being | Neutral or Negative response | 12 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 1: Oral medications | Positive (favorable) response | 20 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 1: Oral medications | Neutral or Negative response | 28 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 2: Nasal sprays | Positive (favorable) response | 24 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 2: Nasal sprays | Neutral or Negative response | 24 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 3: Nasal breathing strips | Positive (favorable) response | 45 Participants |
| Treatment Group - 2 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 3: Nasal breathing strips | Neutral or Negative response | 3 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 3: Feeling fatigued during the day | Positive (favorable) response | 14 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 5: Feelings of embarrassment or self-consciousness | Neutral or Negative response | 17 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 6: Having a good sense of overall well-being | Positive (favorable) response | 38 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 2: Good sleep throughout the night | Neutral or Negative response | 20 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 3: Nasal breathing strips | Neutral or Negative response | 2 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 6: Having a good sense of overall well-being | Neutral or Negative response | 10 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 3: Nasal breathing strips | Positive (favorable) response | 46 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 1: Oral medications | Positive (favorable) response | 17 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 2: Good sleep throughout the night | Positive (favorable) response | 28 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 1: Oral medications | Neutral or Negative response | 31 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 1: Difficulty falling asleep | Positive (favorable) response | 26 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 2: Nasal sprays | Positive (favorable) response | 26 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 1: Difficulty falling asleep | Neutral or Negative response | 22 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 4: Feelings of frustration/restlessness/irritability | Positive (favorable) response | 26 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 3: Feeling fatigued during the day | Neutral or Negative response | 34 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 4: Feelings of frustration/restlessness/irritability | Neutral or Negative response | 22 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 2: Nasal sprays | Neutral or Negative response | 22 Participants |
| Treatment Group - 4 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 5: Feelings of embarrassment or self-consciousness | Positive (favorable) response | 31 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 4: Feelings of frustration/restlessness/irritability | Positive (favorable) response | 29 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 2: Nasal sprays | Neutral or Negative response | 27 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 1: Oral medications | Neutral or Negative response | 28 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 5: Feelings of embarrassment or self-consciousness | Neutral or Negative response | 14 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 2: Good sleep throughout the night | Neutral or Negative response | 25 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 1: Difficulty falling asleep | Positive (favorable) response | 28 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 1: Difficulty falling asleep | Neutral or Negative response | 19 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 6: Having a good sense of overall well-being | Positive (favorable) response | 40 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 3: Feeling fatigued during the day | Positive (favorable) response | 14 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 3: Nasal breathing strips | Neutral or Negative response | 2 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 2: Nasal sprays | Positive (favorable) response | 20 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 6: Having a good sense of overall well-being | Neutral or Negative response | 7 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 2: Good sleep throughout the night | Positive (favorable) response | 22 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 3: Feeling fatigued during the day | Neutral or Negative response | 33 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 5: Feelings of embarrassment or self-consciousness | Positive (favorable) response | 33 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 1: Oral medications | Positive (favorable) response | 19 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 1, Item 4: Feelings of frustration/restlessness/irritability | Neutral or Negative response | 18 Participants |
| Treatment Group - 12 Week Data | Response on Aerin Quality-of-Life (QOL) Assessment Items | Section 2, Item 3: Nasal breathing strips | Positive (favorable) response | 45 Participants |
rTNSS Responder Rate
The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. Subjects who showed at least a 1 point improvement (decrease) in the reflective Total Nasal Symptom Score (rTNSS) were categorized as responders. An overall responder rate of at least 55% was expected.
Time frame: Comparison of scores at Baseline and 12 weeks post procedure
Population: The analyzed population excludes one subject who did not complete the rTNSS questionnaire at the 12 week follow-up visit due to oversight.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| InSeca Stylus Treatment Group | rTNSS Responder Rate | 46 Participants |